• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Appoints Andrew Hider Chief Executive Officer

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care
    Get the next $ATS alert in real time by email

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/

    Andrew Hider Appointed Baxter's Next CEO

    Andrew Hider Appointed Baxter's Next CEO

    Since 2017, Mr. Hider has served as CEO of ATS Corporation (TSX and NYSE:ATS), an industry-leading provider of advanced automation solutions for companies in the life sciences, food and beverage, transportation, consumer products, and energy industries. Under Mr. Hider's leadership, ATS has optimized its portfolio by strategically shifting investments towards higher-growth end markets, while also delivering meaningful margin improvement. Over a five-year period ending with the company's last fiscal year, ATS's adjusted revenues have nearly doubled, representing a low-to-mid teens CAGR (compound annual growth rate) and similar adjusted EBITDA CAGR over the same period1. Since Mr. Hider's appointment in 2017, ATS's stock price has more than tripled on the TSX, significantly outperforming major indices over the same period.

    Like Baxter, ATS is a global, diversified, customer-centric company with a broad scale and range of capabilities. As of 2025, ATS operates 65+ manufacturing facilities globally. ATS's largest end-market is now its life sciences segment where its teams play a critical role enabling the development of automation solutions for medical devices, diagnostic, pharmaceutical, and laboratory operations.

    "Andrew is an exceptional leader with a strong track record of operational excellence, disciplined execution and innovation. We are excited that he will be Baxter's next CEO," said Mr. Shafer. "Andrew's leadership at global, diversified companies underscores his ability to manage complex operations and generate value for shareholders while maintaining a focus on quality and important customer-centric missions. We are confident he is the right executive to lead Baxter into its next chapter."

    "I am energized by Baxter's mission-driven culture and strong legacy of creating medically essential products that help address patients' and customers' most pressing needs," said Mr. Hider. "Baxter has undergone a significant transformation over the last few years, refocusing the company and better positioning it for the future. I look forward to partnering with the Board and working alongside my talented future colleagues to accelerate innovation, further enhance our performance and redefine healthcare delivery while driving sustainable, long-term growth."

    About Andrew Hider

    Andrew Hider brings 25 years of cross-industry experience and global expertise, a growth orientation and an operationally focused, people-centric leadership approach to Baxter. Since 2017, Mr. Hider has served as CEO and a director of ATS, an industry-leading automation solutions provider for multinational customers in markets including life sciences, food and beverage, transportation, consumer products, and energy. Mr. Hider previously served as president and CEO of the Taylor Made Group, LLC, a global leader in the supply of products and systems for marine, transportation, agriculture, and construction markets. Before Taylor Made, Mr. Hider spent 10 years at Danaher Corporation, a leading global life sciences and diagnostics innovator, in various leadership roles, including as president of Veeder-Root, a global supplier of automated tank gauges. Mr. Hider began his career with General Electric Co. in 2000, concluding his six-year tenure as president and general manager of GE Tri-Remanufacturing. In addition, he serves as a member of the board of Tennant Company, which designs, manufactures and sells cleaning products used primarily for non-residential surfaces. Mr. Hider holds a bachelor's degree in interdisciplinary engineering and management and an MBA from Clarkson University.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician's office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 38,000 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    1 Source: ATS Investor Presentation (May 2025). Data is subject to disclaimers set forth in the presentation, including regarding non-lnternational Financial Reporting Standards measures used in this sentence.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250706840140/en/

    Media Contact

    Stacey Eisen, (224) 948-5353

    [email protected]

    Investor Contact

    Clare Trachtman, (224) 948-3020

    Get the next $ATS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATS
    $BAX

    CompanyDatePrice TargetRatingAnalyst
    Baxter International Inc.
    $BAX
    8/4/2025$25.00Buy → Hold
    Stifel
    Baxter International Inc.
    $BAX
    8/1/2025$25.00Buy → Neutral
    Goldman
    Baxter International Inc.
    $BAX
    2/26/2025$42.00Buy
    Goldman
    Baxter International Inc.
    $BAX
    2/24/2025Hold → Buy
    Argus
    Baxter International Inc.
    $BAX
    2/20/2025$39.00Overweight
    Barclays
    Baxter International Inc.
    $BAX
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    Baxter International Inc.
    $BAX
    5/30/2024$36.00Neutral
    Goldman
    Baxter International Inc.
    $BAX
    5/10/2024$40.00Buy → Hold
    TD Cowen
    More analyst ratings

    $ATS
    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and General Counsel Rosenbloom David S. covered exercise/tax liability with 16,548 shares, decreasing direct ownership by 13% to 106,327 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/4/25 4:06:25 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Director Wilkes David S. was granted 7,183 shares, increasing direct ownership by 43% to 23,906 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    5/8/25 4:29:28 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Director Wendell Amy Mcbride was granted 7,183 shares, increasing direct ownership by 30% to 31,222 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    5/8/25 4:28:59 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATS to Participate in the RBC Capital Markets Global Industrials Conference

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that Ryan McLeod, Interim Chief Executive Officer, and Anne Cybulski, Interim Chief Financial Officer, will participate in the RBC Capital Markets Global Industrials Conference in New York City, NY on September 16, 2025. ATS is scheduled to host a break-out session at the event on Tuesday, September 16th, 2025, at 10:40 a.m. ET. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your RBC Capital Markets representative or [email protected]. About ATS Corporation ATS Corporation is an industry-leading automation solutions provider to many of th

    8/14/25 5:00:00 PM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    ATS to Participate in the Jefferies Industrials Conference

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that Ryan McLeod, Interim Chief Executive Officer, and Anne Cybulski, Interim Chief Financial Officer, will participate in the Jefferies Industrials Conference in New York City, NY on September 4, 2025. ATS is scheduled to host a fireside chat at the event at 10:10 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in the Events & Presentations section. A replay of the webcast will be available on the same website for 180 days. Management will also host institutional investor meetings at the Conference, which can be arranged by c

    8/14/25 5:00:00 PM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    ATS to Participate in the Raymond James Industrial Showcase

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that Ryan McLeod, Interim Chief Executive Officer, and Anne Cybulski, Interim Chief Financial Officer, will participate in the virtual Raymond James Industrial Showcase on August 13, 2025. Management will host institutional investor meetings at the Showcase, which can be arranged by contacting your Raymond James representative or [email protected]. About ATS Corporation ATS Corporation is an industry-leading automation solutions provider to many of the world's most successful companies. ATS uses its extensive knowledge base and global capabilities in custom automation, repeat automation, automation p

    8/8/25 5:00:00 PM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    $ATS
    $BAX
    Financials

    Live finance-specific insights

    View All

    ATS Reports First Quarter Fiscal 2026 Results

    ATS Corporation (TSX and NYSE:ATS) ("ATS" or the "Company") today reported its financial results for the three months ended June 29, 2025. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. First quarter highlights: Revenues increased 6.1% year over year to $736.7 million. Net income was $24.3 million compared to $35.3 million a year ago. Basic earnings per share were 25 cents, compared to 36 cents a year ago. Adjusted EBITDA1 was $101.5 million compared to $106.0 million a year ago. Adjusted basic earnings per share1 were 41 cents compared to 50 cents a year ago. Order Bookings2 were $693 million, 15.2% lower comp

    8/7/25 6:00:00 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Baxter Reports Second-Quarter 2025 Results

    Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company's previously issued guidance1,2 Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing operations of $0.59, in line with the company's previously issued guidance Recently announced appointment of Andrew Hider as president and chief executive officer (CEO)4 supports company's focus to accelerate innovation, drive sustainable growth, enhance operational effectiveness and create shareholder value Baxter International Inc. (NYSE:BAX), a global medtech lead

    7/31/25 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    ATS Announces Dates of First Quarter Results Conference Call and Annual Meeting of Shareholders

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") will report its financial results for the first quarter ended June 29, 2025, before markets open on Thursday August 07, 2025. At 8:30 a.m. Eastern on August 07, 2025, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/857742136 and the conference call can be accessed by dialing (888) 660-6652 five minutes prior and quoting reference number 8782510. A replay of the conference will be available on the ATS website following the call. Alternatively, a telephone rec

    7/23/25 5:00:00 PM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    $ATS
    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    ATS Announces CEO Departure

    ATS Corporation (TSX:ATS) (NYSE:ATS) ("ATS" or the "Company") today announced that Andrew Hider will be stepping down from his role as Chief Executive Officer of the Company and from its Board of Directors (the "Board") to pursue a new leadership opportunity outside the automation industry. The effective date for Mr. Hider's departure from the Company is expected to be by the end of August on a date to be determined by the Board. As a result of the foregoing, Mr. Hider will be withdrawing his candidacy for election to the Board at the Company's upcoming Annual General Meeting ("AGM") being held on August 7th, 2025. The Company will be filing an amendment to its management information circul

    7/7/25 8:30:00 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Goldman resumed coverage on Baxter with a new price target

    Goldman resumed coverage of Baxter with a rating of Buy and set a new price target of $42.00

    2/26/25 7:01:30 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $ATS
    $BAX
    SEC Filings

    View All

    SEC Form 6-K filed by ATS Corporation

    6-K - ATS Corp /ATS (0001394832) (Filer)

    8/15/25 8:53:07 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by ATS Corporation

    6-K - ATS Corp /ATS (0001394832) (Filer)

    8/15/25 8:48:23 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by ATS Corporation

    6-K - ATS Corp /ATS (0001394832) (Filer)

    8/12/25 8:56:45 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    $ATS
    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ATS Corporation

    SC 13G/A - ATS Corp /ATS (0001394832) (Subject)

    11/13/24 10:27:59 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by ATS Corporation

    SC 13G/A - ATS Corp /ATS (0001394832) (Subject)

    11/13/24 9:14:58 AM ET
    $ATS
    Industrial Machinery/Components
    Industrials